A round up of all the latest news on www.globaluniversityventuring.com for our subscribers.
Universities inject IP into Serenta
Serenta, which develops vaccines targeting chronic infections, has obtained a licence for a vaccine against bacteria that have proven resistant to antibiotics.
SpeedyCloud fastens $14.7m series B
Chinese Academy of Sciences has led a series B round through Cash Capital, while an unnamed unit of the institution entered a strategic partnership with SpeedyCloud.
Lung Therapeutics inhales $14.3m
The UT Horizon Fund has participated in a $14.3m series B round for Lung Therapeutics.
Coursera graduates series D with $64m
Universities-backed online education provider Coursera is reportedly valued at $800m after closing a series D round that will support its new enterprise-focused product.
PharmaCell, a spinout of Brightlands Maastricht Health Campus, has been acquired by Lonza.
Imperial College grows incubator
The university has moved its incubator to a new campus and a bigger facility.
Stanley Ventures speeds up Veloxint
Stanley Ventures, the corporate venturing arm of Stanley Black & Decker, has provided an undisclosed amount to MIT spinout Veloxint.
Spun out of Queensland and Emory universities, the biotech developer has secured capital from Uniseed and the Medical Research Commercialisation Fund.
The Duke University spinout has secured capital from 10 unnamed investors.
Evolve BioSystems grows up with $20m
The UC Davis spinout has collected $20m in series B capital from Bow Capital, a VC fund affiliated with the university.
Pittsburgh to lead $200m revolution
The Pittsburgh Revolution Fund is expected to support research commercialisation from the university’s Drug Discovery Institute.
Existing shareholders, including IP Group and Finance Wales, have supplied additional capital to Cardiff spinout Alesi Surgical.
Court Innovations finds in favour of series A
A spinout of University of Michigan’s Law School, Court Innovations has secured $1.8m from investors including the institution’s student-led Social Venture Fund.
Scenic Biotech switches on series A
Based on research conducted at University of Oxford and Netherlands Cancer Institute, Scenic Biotech has raised $7.3m to commercialise technology that tackles diseases on the genetic level.
